2018-05-09T18:31:03-05:00 2017-06-30 ERNST & YOUNG US LLP 4370 LA JOLLA VILLAGE DR STE 500 SAN DIEGO CA 92122 990 2016-07-01 952160097 THE SALK INSTITUTE FOR BIOLOGICAL STUDIES % KIMBERLY CASTILLO SALK 8584534100 10010 N TORREY PINES ROAD LA JOLLA CA 920371002 KIMBERLY CASTILLO CFO 8584534100 2018-05-07 true JOCELYNE MILLER P00634378 8585357200 2016 2022-09-23 18:48:47Z FRED GAGE 10010 N TORREY PINES ROAD LA JOLLA CA 920371002 324923787 false X WWW.SALK.EDU X 1960 CA BASIC RESEARCH IN THE FOLLOWING: MOLECULAR BIOLOGY & GENETICS, NEUROSCIENCE, AND PLANT BIOLOGY. 33 30 1041 144 36544 22570 101155413 117967625 0 0 24667404 12519420 2387202 1372745 128210019 131859790 0 0 0 0 65706375 68371000 0 0 4424614 51166322 50993264 116872697 119364264 11337322 12495526 456410477 500598954 108429751 115532386 347980726 385066568 X INVOLVED IN RESEARCH ACTIVITIES, THE OBJECTIVES OF WHICH ARE THE ADVANCEMENT AND DISSEMINATION OF KNOWLEDGE RELEVANT TO THE HEALTH AND WELLBEING OF MAN. THE OBJECTIVES ARE MET PRIMARILY THROUGH RESEARCH AND ADVANCED INSTRUCTION IN (A) BIOLOGY, (B) THE CAUSE, PREVENTION AND CURE OF DISEASES, AND (C) THE FACTORS AND CIRCUMSTANCES CONDUCIVE TO THE FULFILLMENT OF MAN'S BIOLOGICAL POTENTIAL. false false 100243398 0 0 Small molecule keeps new adult neurons from straying, may be tied to schizophrenia - Scientists at the Salk Institute discovered that a small stretch of ribonucleic acid, a molecule called miR-19, guides the placement of new neurons in the adult brain. This molecule is disrupted in cells from patients with schizophrenia. The findings, published in Neuron, represent one of the first links between an individual microRNA and a specific process in the brain or a brain disorder. The discovery could lead to a better understanding of how the adult brain controls the growth of new neurons and how it can go wrong. [7/6/16] New neurons reveal clues about an individuals autism - Autism, affecting approximately 1 out of every 68 children in the United States, has no known cause, although the brains of some people with this disorder grow faster than usual early in life. A study co-led by Salk Institute scientists began unraveling the mechanisms driving excess brain growth by creating neuron precursor cells from this population subset and observing that these stem cell-derived neurons multiplied faster in the dish than those of healthy individuals. The cells also made fewer connections compared to cells from healthy individuals. The team restored communications between the cells by adding IGF-1, a drug currently being evaluated in clinical trials of autism. The findings were published in Molecular Psychiatry. [7/7/16] When it comes to recognizing shapes, timing is everything - Salk researchers showed how vision relies on patterns of brain activity from a brain area called V4, which picks out the boundaries of objects. In a study published in Neuron, the team used data from neuronal electrical activity in V4 to create a computer code they dubbed an "ideal observer". With access to only the brain data, the computer "deciphered" moving pictures. One version of the ideal observer relied on the number of times the neurons fired; the other version used both the number and the timing of the firings. The latter observer correctly guessed the moving images more than twice as accurately as the more basic observer. Better understanding the links between patterns of neuron activity and how the brain sees the world could lay the groundwork for more advanced visual prosthetics. [8/4/16] Disregarded plant molecule actually a treasure - By using an array of cutting-edge biological approaches, Salk scientists revealed that a plant molecule called phaseic acid, often overlooked by plant biologists, plays a critical role in developing hardier plants. Their work, published in Cell, suggests that phaseic acid, along with abscisic acid, helps move carbon from a plants leaves and stems into its roots to protect them during periods of drought, overwintering and during pathogen attacks in the soil. A greater understanding of this area of plant biology could provide new leads into the development of hardier food crops that can weather natural disasters wrought by climate change. [8/11/16] New mechanism discovered for Alzheimers risk gene - People with two copies of a gene called apolipoprotein E4 (ApoE4) are much more likely to have Alzheimers disease at age 65 than the rest of the population. Researchers at the Salk Institute identified a new connection between ApoE4 and the protein build-up associated with Alzheimers, an enzyme called high-temperature requirement serine peptidase A1 (HtrA1), which provides a possible biochemical explanation for how extra ApoE4 causes the disease. Their findings, reported in the Journal of the American Chemical Society, provide a new avenue for making progress in understanding Alzheimers. [8/17/16] Neurodevelopmental model of Williams syndrome offers insight into human social brain - By employing cutting-edge stem cell techniques, Salk scientists and their collaborators were able to, for the first time, directly observe the behavior of cells with the genetic profile of Williams syndrome, a rare genetic condition that affects approximately 20,000 Americans. The findings were published in the online edition of Nature. One aspect of Williams syndrome, which causes a host of medical problems, is a hyper-social predisposition. The neurodevelopmental model created by the scientific team may provide new insights into the fundamental biological processes underlying social interactions. [8/20/16] Elevating brain protein allays symptoms of Alzheimers and improves memory - Scientists at the Salk Institute discovered that boosting levels of a specific protein, neuregulin-1, in the brain alleviates hallmark features of Alzheimers disease in a mouse model of the disorder. When they raised the level of neuregulin-1 in the hippocampus, an area of the brain responsible for learning and memory, the mice showed improved performance on a test of spatial memory. Neuregulin-1 has many forms and functions across the brain and is already a potential target for such brain disorders as Parkinsons disease, amyotrophic lateral sclerosis and schizophrenia. The Salk teams findings were described in Scientific Reports. [8/25/16] Salk scientists map brains action center - Using genetic engineering, cutting-edge neuronal tracing and electrophysiology, Salk researchers created a comprehensive map of the connectivity of neurons within the striatum, a part of the brain that helps control movement toward a goal. The exact functions of the striatum and its ability to coordinate many diverse functions is still a mystery, but when the striatum doesnt operate properly, it can lead to disorders such as Parkinsons disease, obsessive-compulsive disorder or addiction. The Salk study, published in Neuron, adds crucial insights into the mechanisms that drive brain disorders. [8/25/16] New method creates endless supply of kidney precursor cells - In a scientific breakthrough, Salk researchers successfully created kidney progenitor cells that survive in the lab. Previous attempts to maintain cultures of nephron progenitor cells often failed, as the cells died or gradually lost their developmental potential. By using a 3D culture and a new mixture of supporting molecules, the Salk researchers successfully suspended the cells early in their development. The work, published in Cell Stem Cell, holds tremendous promise for regenerative therapy to replace ailing organs, as well as modeling diseases in the lab. [8/25/16] The brains stunning genomic diversity revealed - Most cells in the human brain have changes to their DNA that make each neuron a little different. A multi-institute collaboration led by the Salk Institute showed that one source of this variation - long interspersed nuclear elements (or L1s) - are present in 44 to 63 percent of healthy neurons and can not only insert DNA but also remove it. The discovery, published in Nature Neuroscience, may help explain what makes each human unique and provide new insights into diseases linked with more than normal amounts of L1 variations, such as schizophrenia and autism. [9/9/16] Targeting fat to treat cancer - Cells create their own fat molecules to build plasma membranes and other structures, and a critical player in lipid synthesis is the enzyme acetyl-CoA carboxylase (ACC). Knowing that cancer cells are especially reliant on lipid synthesis, researchers at the Salk Institute collaborated with biotechnicians to identify a novel ACC inhibitor, dubbed ND-646. In large-scale testing of ND-646 in both animal models of cancer and in transplanted human lung cancer cells, the team observed tumor masses shrink by two-thirds. When the researchers paired ND-646 with carboplatin, a common treatment for non-small lung cancer, 87% of tumors were suppressed. This important work was published in Nature Medicine. [9/19/16] Salk scientists adapt computer program to gauge eye spasm severity - To provide an objective scale for research and diagnosis of blepharospasm - uncontrollable muscle contractions around the eye - Salk scientists developed a computer program that analyzes videos of patients faces. The new tool, described online in Neurology, could eventually be expanded to help study facial tics and twitches in other contexts, including Tourette syndrome, schizophrenia and Parkinsons disease. [10/21/16] Heart disease, leukemia linked to dysfunction in nucleus - Investigations by Salk scientists showed that the cells nuclear membrane, far from being a passive enclosure as previously thought, is an active regulatory structure. The findings were reported in Genes & Development. Using a suite of molecular biology technologies, the Salk team discovered that two proteins in the nuclear envelope, together with the membrane-spanning complexes they form, actively associate with stretches of DNA to trigger expression of key genes. Better understanding these higher-level functions could provide insight into diseases that appear to be related to dysfunctional nuclear membrane components, such as leukemia, heart disease and aging disorders. [11/2/16] "Prince 100243398 true true false true false false false false false true true true false false true false true false false false true false false false true false false false false true true false false false false false true false false false false true false false false false true true false false false true 130 0 true 1041 true true true false false false false true true false false false false X 33 30 false false false false true true true true true false false true true true true true true true true false AL AK AZ AR CA CT GA HI IL KS KY ME MD MA MI MN MS NH NJ NM NY NC OH OK OR PA RI SC TN UT VA WA WV WI X X KIMBERLY CASTILLO 8584534100 10010 N TORREY PINES ROAD LA JOLLA CA 920371002 X IRWIN M JACOBS SM SCD CHAIR (OUTGOING 11/18/16) 3.0 0.0 X X 0 0 0 M FAYE WILSON TRUSTEE 0.5 0.0 X 0 0 0 DANIEL C LEWIS TRUSTEE 2.0 0.0 X 0 0 0 THEODORE WAITT CHAIR (INCOMING 11/19/16) 3.0 0.0 X X 0 0 0 MARNA WHITTINGTON PHD VICE CHAIR 2.0 0.0 X X 0 0 0 RICHARD A HEYMAN PHD VICE CHAIR 2.0 0.0 X X 0 0 0 ELIZABETH BLACKBURN PHD PRESIDENT 50.0 0.0 X X 930438 0 8248 EDWARD M CALLAWAY PHD TRUSTEE/PROFESSOR 50.0 0.0 X 344109 0 44136 DONALD L COHN TRUSTEE 0.5 0.0 X 0 0 0 FREDERICK J DOTZLER TRUSTEE 2.0 0.0 X 0 0 0 JAY FLATLEY TRUSTEE 0.5 0.0 X 0 0 0 ALAN D GOLD TRUSTEE 0.5 0.0 X 0 0 0 DAVID F HALE TRUSTEE 0.5 0.0 X 0 0 0 MARTIN HETZER PHD PROFESSOR/CSO 50.0 0.0 X 296664 0 43790 EDWIN K HUNTER TRUSTEE 0.5 0.0 X 0 0 0 THOMAS M JESSELL PHD TRUSTEE 0.5 0.0 X 0 0 0 SANJAY K JHA PHD TRUSTEE 2.0 0.0 X 0 0 0 ELIZABETH KEADLE TRUSTEE 2.0 0.0 X 0 0 0 BENJAMIN H LEWIS TRUSTEE 0.5 0.0 X 0 0 0 CORINNE MENTZELOPOULOS TRUSTEE 0.5 0.0 X 0 0 0 HOWARD H NEWMAN PHD TRUSTEE 2.0 0.0 X 0 0 0 JOSEPH NOEL PHD TRUSTEE/PROFESSOR 50.0 0.0 X 0 0 0 FREDERIK PAULSEN PHD TRUSTEE 0.5 0.0 X 0 0 0 ERNEST S RADY TRUSTEE 0.5 0.0 X 0 0 0 MARKUS REINHARD TRUSTEE 0.5 0.0 X 0 0 0 TERRY ROSEN PHD TRUSTEE 0.5 0.0 X 0 0 0 ERIC SAGERMAN TRUSTEE 0.5 0.0 X 0 0 0 ALAN SAGHATELIAN PHD TRUSTEE/PROFESSOR 50.0 0.0 X 222280 0 19748 MARY JANE SALK TRUSTEE 0.5 0.0 X 0 0 0 BENJAMIN S SCHAPIRO TRUSTEE 2.0 0.0 X 0 0 0 STACEY STEWART TRUSTEE 0.5 0.0 X 0 0 0 HAEYOUNG KONG TANG PHD TRUSTEE 0.5 0.0 X 0 0 0 DANIEL TIERNEY TRUSTEE 0.5 0.0 X 0 0 0 JOON YUN MD TRUSTEE 0.5 0.0 X 0 0 0 JENNIFER L HOWSE PHD TRUSTEE 0.5 0.0 X 0 0 0 FAYE HUNTER TRUSTEE 0.5 0.0 X 0 0 0 HARVEY P WHITE TRUSTEE 0.5 0.0 X 0 0 0 JULIA A MILLER JD SECRETARY/GENERAL COUNSEL 50.0 0.0 X 284593 0 45779 KIM E WITMER TREASURER/SVP FINANCE & ADMIN 50.0 0.0 X 440522 0 46087 KIMBERLY CASTILLO CHIEF FINANCIAL OFFICER 50.0 0.0 X 239801 0 37161 JENNEFER COLLINS VP, ACADEMIC & ADMIN SVCS 50.0 0.0 X 325298 0 45745 FRED GAGE PHD PROFESSOR 50.0 0.0 X 368067 0 42984 ANTHONY HUNTER PHD PROFESSOR 50.0 0.0 X 338429 0 40122 REBECCA NEWMAN VP, EXTERNAL RELATIONS 50.0 0.0 X 487419 0 34459 INDER VERMA PHD PROFESSOR 50.0 0.0 X 417484 0 42984 WILLIAM R BRODY MD PHD FORMER PRESIDENT 0.0 0.0 X 105000 0 0 MARSHA A CHANDLER PHD FORMER EXEC.VP/COO 0.0 0.0 X 318316 0 0 5118420 0 451243 96 true true false UC REGENTS SAN DIEGO 9500 GILMAN DRIVE LA JOLLA CA 92093 TRNG PROGRAM/SUBCONT 2242675 Rudolph Sletten 600 B STREET SUITE 1500 SAN DIEGO CA 92101 CONSTRUCTION SVCS 6776705 ALLIED BARON SECURITY SERVICES 161 WASHINGTON STREET SUITE 600 CONSHOHOCKEN PA 19428 SECURITY SERVICE 497158 WISS JANEY ELSTNER ASSOCIATES 330 PFINGSTEN ROAD NORTHBROOK IL 60062 CONSTRUCTION SVCS 326900 A O REED CO 4777 RUFFNER STREET SAN DIEGO CA 92111 CONSTRUCTION SVCS 273053 11 1130441 47727245 69109939 7234784 117967625 0 706937 706937 0 1474874 1474874 0 0 0 204567990 192755507 11812483 11812483 11812483 99192 1130441 308490 -209298 -209298 0 0 0 0 0 0 ENERGY REBATE 900099 65276 65276 OIL ROYALTIES 900099 1714 1714 UBI(K-1 FLOW THROUGH INCOME) 900099 36544 36544 3635 3635 107169 131859790 36544 13855621 0 0 0 0 3426672 970726 2247209 208737 0 49652581 42453851 5247267 1951463 3565348 2947401 438858 179089 8135063 6889234 1001343 244486 3591336 2968885 442057 180394 390538 80000 310538 479643 163162 314068 2413 225247 225247 0 0 113650 113650 10985291 9466087 1255492 263712 56380 13087 7203 36090 1179204 503868 331733 343603 2300710 1790116 417310 93284 0 6225821 4968600 1117415 139806 1283064 704455 146775 431834 0 1173555 872427 136958 164170 38079 38079 0 10196744 9315589 711091 170064 147422 147422 SCIENTIFIC SUBCONTRACTS 3248760 3248760 RESEARCH SUPPLIES 12607341 12607341 REPAIRS & PARTS 286737 281317 4015 1405 OTHER EXPENSES 74078 -1508 61522 14064 -19000 -19000 119364264 100243398 14696252 4424614 11957234 9627314 0 0 36961022 39612337 469892 759707 447167 529057 0 0 1890000 1667867 44417 63157 1110427 846651 242811853 165162418 72683855 77649435 187364191 161699053 138309614 202608567 0 0 0 0 5172658 5535809 456410477 500598954 19668698 21252910 0 0 25931051 24535990 55810947 63236995 0 0 0 0 0 0 0 0 7019055 6506491 108429751 115532386 X 80301928 88141016 90775336 110129823 176903462 186795729 347980726 385066568 456410477 500598954 X 12495526 24070496 519820 X false true X true true true X 131344685 138079570 106020719 101155413 117967625 594568012 0 0 131344685 138079570 106020719 101155413 117967625 594568012 26067818 568500194 4331506 4920223 8686425 5072963 2181811 25192928 3701 12021 45497 61219 170454 176715 185573 174543 70625 777910 620600069 0.91605 0.90467 X OTHER INCOME SCHEDULE A, PART II, LINE 10 Description: OIL ROYALTIES 2012: 2,951 2013: 5,788 2014: 4,629 2015: 2,022 2016: 1,714 Description: NOTE RECEIVABLE INTEREST 2012: 462 2013: 0 2014: 0 2015: 0 2016: 0 Description: ENERGY REBATE 2012: 167,503 2013: 145,516 2014: 179,409 2015: 169,137 2016: 65,276 Description: POSTRETIREMENT BENEFITS 2012: 0 2013: 21,588 2014: 0 2015: 0 2016: 0 Description: REVENUE SHARING-HOST VEHICLE CHARGING STATION 2012: 0 2013: 0 2014: 690 2015: 0 2016: 0 Description: RECYCLING/VAN SALE 2012: 0 2013: 2,333 2014: 0 2015: 0 2016: 0 Description: NET GIFT SHOP SALES 2012: 0 2013: 1,490 2014: 845 2015: 3,384 2016: 3,635 RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED false false false false false false false false true 2508 2508 false OTHER ACTIVITIES PART II-B, LINE 1 PAID MEMBERSHIP DUES TO RESEARCH AND BIOMEDICAL ORGANIZATIONS, A PORTION OF WHICH ARE CONSIDERED LOBBYING. ASSOCIATION OF INDEPENDENT RESEARCH INSTITUTES $1,060 NATIONAL ASSOCIATION FOR BIOMEDICAL RESEARCH $1,200 BIOCOM $248 207522930 10092267 18861980 7508657 228968520 218699419 6197345 -10186871 7186963 207522930 218629544 5364024 1892814 7186963 218699419 167637178 29641230 27636790 6285654 218629544 126725558 24531449 20361663 3981493 167637177 0.01710 0.98290 false false 1153930 1153930 160325788 100679086 59646702 80068076 63230287 16837789 1264059 1253045 11014 77649435 ALTERNATIVE INVESTMENTS 202605556 F STOCKS NOT-PUBLICLY TRADED <5% 3011 C 202608567 2052 DEFERRED RETIREE MEDICAL OBLIGATION 6504439 6506491 133892582 24070496 -22309652 1760844 132131738 -271948 -271948 131859790 119672751 308490 308490 119364261 3 3 119364264 ENDOWMENT FUNDS USES PART V, LINE 4 ENDOWMENT INCOME INTENDED TO BE USED FOR AND TO SUPPORT RESEARCH, OPERATIONS, AND LECTURESHIP EXPENSES. RECONCILIATION OF REVENUE PER AUDITED FS WITH REVENUE PER RETURN PART XI, LINE 2D INVESTMENT RETURN IN EXCESS OF AMOUNT DESIGNATED FOR CURRENT OPERATIONS UNDER SPENDING POLICY AND ROUNDING. Reconciliation of Revenue per Audited FS with Revenue per Return PART XI, LINE 4B FUNDRAISING EVENTS EXPENSES ($308,490), UNRELATED BUSINESS INCOME $36,544, AND ROUNDING ($2). Reconciliation of Expenses per Audited Financial Stmts w Expenses per Rtn PART XII, LINE 2D FUNDRAISING EVENTS EXPENSES. PART XII, LINE 4B ROUNDING. Europe (Including Iceland and Greenland) Program Services Attended conference 236869 East Asia and the Pacific Program Services Attended conference 49197 South Asia Program Services Attended conference 2193 Middle East and North Africa Program Services Attended conference 443 South America Program Services Attended conference 399 North America Program Services Attended conference 173 Europe (Including Iceland and Greenland) Program Services Scientific subcontract 30022 Central America and the Caribbean Investments 77826588 Europe (Including Iceland and Greenland) Investments 41667871 Sub-Saharan Africa Investments 7337362 North America Investments 174927 Russia and the Newly Independent States Fundraising 350683 127676727 127676727 true false true true true false NO. OF EMPLOYEES IN THE REGION PART I, LINE 3, COLUMN (C) SCIENTISTS TRAVEL TO FOREIGN COUNTRIES TO ATTEND CONFERENCES. WE DO NOT DEEM THESE ACTIVITIES TO CONSTITUTE WORKING IN THE REGION. ACCOUNTING METHOD PART I, LINE 3, COLUMN (F) ACCRUAL METHOD CONCERT 1168356 1094806 73550 97862 160125 LECTURE/MUSIC 61277 35635 25642 3203 47300 0 1229633 1130441 99192 101065 207425 308490 -209298 X X true true X X X X X X true false false false false false false false false ELIZABETH BLACKBURN PHD PRESIDENT 748570 0 0 0 181868 0 5300 0 2948 0 938686 0 0 0 JULIA A MILLER JD SECRETARY/GENERAL COUNSEL 281875 0 0 0 2718 0 31800 0 13979 0 330372 0 0 0 KIM E WITMER TREASURER/SVP FINANCE & ADMIN 373778 0 0 0 66744 0 31800 0 14287 0 486609 0 0 0 EDWARD M CALLAWAY PHD TRUSTEE/PROFESSOR 248115 0 0 0 95994 0 30700 0 13436 0 388245 0 0 0 MARTIN HETZER PHD PROFESSOR/CSO 244617 0 0 0 52047 0 31190 0 12600 0 340454 0 0 0 ALAN SAGHATELIAN PHD TRUSTEE/PROFESSOR 196755 0 0 0 25525 0 10079 0 9669 0 242028 0 0 0 JENNEFER COLLINS VP, ACADEMIC & ADMIN SVCS 285899 0 0 0 39399 0 31800 0 13945 0 371043 0 0 0 FRED GAGE PHD PROFESSOR 357795 0 0 0 10272 0 31800 0 11184 0 411051 0 0 0 ANTHONY HUNTER PHD PROFESSOR 319134 0 0 0 19295 0 26500 0 13622 0 378551 0 0 0 REBECCA NEWMAN VP, EXTERNAL RELATIONS 370820 0 0 0 116599 0 31800 0 2659 0 521878 0 0 0 INDER VERMA PHD PROFESSOR 407212 0 0 0 10272 0 31800 0 11184 0 460468 0 0 0 WILLIAM R BRODY MD PHD FORMER PRESIDENT 5000 0 0 0 100000 0 0 0 0 0 105000 0 0 0 MARSHA A CHANDLER PHD FORMER EXEC.VP/COO 0 0 0 0 318316 0 0 0 0 0 318316 0 0 0 KIMBERLY CASTILLO CHIEF FINANCIAL OFFICER 223631 0 0 0 16170 0 23685 0 13476 0 276962 0 0 0 QUESTIONS REGARDING COMPENSATION PART I, LINE 1A FIRST-CLASS OR CHARTER TRAVEL: ELIZABETH BLACKBURN, PRESIDENT - $12,310; EDWARD CALLAWAY, PROFESSOR - $1,766; FRED GAGE, PROFESSOR - $4,751; REBECA NEWMAN, VP-EXTERNAL RELATIONS - $9,003; INDER VERMA, PROFESSOR - $598. NOT TAXABLE - ACCOUNTABLE PLAN. QUESTIONS REGARDING HOUSING ALLOWANCE OR RESIDENCE PART I, LINE 1A A HOUSING ALLOWANCE IS PROVIDED AND REPORTED AS TAXABLE COMPENSATION. SEVERANCE PAYMENT PART I, LINE 4A SEVERANCE PAYMENT BASED ON CONFIDENTIAL AGREEMENT A COUNTY OF SAN DIEGO 956000934 797391R50 2010-05-27 37207949 REFUND 04/30/00 ISSUE;RENOVATE/EQU false false false B CA STATEWIDE COMM DEV AUTHORITY 680164610 2014-08-07 31081050 REFUND 08/11/05 ISSUE;RENOVATE/EQU false false false A 2160000 0 37207949 0 0 0 523682 0 0 23742247 12942020 0 2012 false true true true B 610535 0 29921340 0 0 0 0 0 0 13840290 16081050 0 true false false true A false false false false 0 false false false true B false false false false 0 false false false true A false false false true false false 0 false 0 false true B false true false false false 0 false 0 false true A true B true Schedule K, Part IV, Line 2c The rebate calculation was last performed on 05/10/2015. EDWARD CALLAWAY PROFESSOR RETENTION X 150000 100000 false true true ALAN SAGHATELIAN PROFESSOR HOME LOAN X 200000 150000 false true true MARTIN HETZER PROFESSOR HOME LOAN X 200000 155724 false true true MARTIN HETZER PROFESSOR HOME LOAN X 221500 98444 false true true MARTIN HETZER PROFESSOR HOME LOAN X 56000 24889 false true true 529057 X 38 7234784 MARKET VALUE false true false NUMBER OF CONTRIBUTIONS PART I, COLUMN B THE AMOUNT REPORTED IN THIS COLUMN REPRESENTS THE NUMBER OF CONTRIBUTIONS. GOVERNING BODY AND MANAGEMENT FORM 990, PART VI, SECTION A, LINES 1A, 6, 7A, 7B LINE 1A: THE EXECUTIVE COMMITTEE SHALL ADVISE AND AID THE OFFICERS OF THE CORPORATION IN ALL MATTERS CONCERNING ITS INTERESTS, INCLUDING WITHOUT LIMITATION ALL MATTERS RELATING TO COMPENSATION AND BENEFITS, AND SHALL POSSESS AND MAY EXERCISE, DURING THE INTERVALS BETWEEN THE MEETINGS OF THE BOARD OF TRUSTEES, ALL THE POWERS AND AUTHORITY OF THE BOARD OF TRUSTEES IN THE MANAGEMENT OF THE BUSINESS AND AFFAIRS OF THE CORPORATION, INCLUDING THE POWER TO AUTHORIZE THE CORPORATE SEAL TO BE AFFIXED TO ANY AND ALL DOCUMENTS WHICH MAY REQUIRE THE SAME TO BE AFFIXED THERETO, INSOFAR AS SUCH SEEMS TO THE EXECUTIVE COMMITTEE FOR THE BEST INTERESTS OF THE CORPORATION, IN ALL CASES IN WHICH SPECIFIC DIRECTIONS SHALL NOT HAVE BEEN GIVEN BY THE BOARD OF TRUSTEES, EXCEPT THAT THE EXECUTIVE COMMITTEE SHALL HAVE NO POWER TO ADOPT, AMEND, OR REPEAL THE BY-LAWS. LINE 6: MEMBERSHIP OF THE CORPORATION CONSISTS OF THE PERSONS ELECTED TO THE BOARD OF TRUSTEES AND THREE MEMBERS FROM AMONG THE RESIDENT AND NON-RESIDENT FELLOWS AND PROFESSORS CHOSEN AND ELECTED ANNUALLY BY THE RESIDENT AND NON-RESIDENT FELLOWS AND PROFESSORS. LINE 7A: THE MEMBERS OF THE CORPORATION ELECT THE TRUSTEES. LINE 7B: THE MEMBERS OF THE CORPORATION MAY ALTER, AMEND, OR REPEAL THE BY-LAWS BY VOTE. POLICIES FORM 990, PART VI, SECTION B, LINES 11B, 12C, 15A/B LINE 11B: THE FORM 990 IS PREPARED BY THE INSTITUTE, INTERNALLY REVIEWED BY THE CHIEF FINANCIAL OFFICER AND EXTERNALLY REVIEWED BY THE TAX DEPARTMENT OF A PUBLIC ACCOUNTING FIRM. A COPY OF THE PREPARED FORM 990 IS PROVIDED TO ALL BOARD MEMBERS AND THE AUDIT COMMITTEE FOR REVIEW AND DISCUSSION PRIOR TO ELECTRONIC FILING. LINE 12C: ANNUALLY, THE CONFLICT OF INTEREST DISCLOSURE STATEMENT IS SENT OUT FOR COMPLETION BY THE MEMBERS OF THE BOARD OF TRUSTEES, SENIOR MEMBERS OF ADMINISTRATION AND RESEARCHERS. THE DESIGNATED OFFICIAL FOR EACH GROUP REVIEWS THE COMPLETED FORMS AND BRINGS ANY POTENTIAL CONFLICT OF INTEREST TO THE RESPECTIVE COMMITTEES FOR REVIEW. UPON DETERMINATION THAT A CONFLICT OF INTEREST EXISTS, THE FOLLOWING CONDITIONS OR RESTRICTIONS MAY BE IMPOSED: A. MONITORING OF ACTIVITIES GENERATING THE CONFLICT BY ANOTHER MEMBER; B. DISQUALIFICATION FROM PARTICIPATION IN THE ACTIVITIES GIVING RISE TO THE CONFLICT; C. MODIFICATION OF RESPONSIBILITIES TO AVOID CONFLICTS; D. PUBLIC DISCLOSURE OR DIVESTITURE OF SIGNIFICANT FINANCIAL INTERESTS; E. MODIFICATION OF THE RESEARCH PLAN OR REMOVAL OF THE AFFECTED RESEARCHER FROM THE RESEARCH; F. SEVERANCE OF RELATIONSHIP THAT CREATES ACTUAL OR POTENTIAL CONFLICTS; G. TERMINATION OF EMPLOYMENT. LINE 15A/B:IN FISCAL YEAR 2017 (JULY 1, 2016 JUNE 30, 2017), AN INDEPENDENT CONSULTANT WAS RETAINED BY THE SALK INSTITUTE TO ANALYZE AND ADVISE ON THE COMPETITIVENESS OF THE BASE SALARY AND TOTAL COMPENSATION (INCLUDING BENEFITS) FOR THE VICE PRESIDENT, EXTERNAL RELATIONS. TOTAL COMPENSATION WAS COMPARED TO LIKE ROLES AMONG ORGANIZATIONS PROVIDING SIMILAR SERVICES IN THE RESEARCH INDUSTRY, INCLUDING BOTH FOR-PROFIT AND NOT-FOR-PROFIT ORGANIZATIONS. THE CONSULTANT CONSIDERED THE SIZE AND SCOPE OF OPERATIONS OF THE INCUMBENT AND THE GUIDELINES ARTICULATED IN THE SALK INSTITUTE EXECUTIVE COMPENSATION POLICY. THE CONSULTANT GAVE THE OPINION THAT THE METHODOLOGY EMPLOYED FOR THAT PERIOD FOR EXECUTIVE COMPENSATION RECOMMENDATIONS AND DECISIONS WAS APPROPRIATE TO ESTABLISH REASONABLENESS. HUMAN RESOURCES COMPLETED A SIMILAR TOTAL COMPENSATION ANALYSIS FOR ALL EXECUTIVES. THE COMPENSATION COMMITTEE WAS PROVIDED MARKET DATA COMPARISON TO LIKE ROLES AMONG ORGANIZATIONS PROVIDING SIMILAR SERVICES IN THE RESEARCH INDUSTRY AND NOT-FOR-PROFIT SECTORS. HUMAN RESOURCES GAVE THE OPINION THAT THE TOTAL COMPENSATION WAS WELL WITHIN THE REASONABLE RANGE OF COMPETITIVE PRACTICES AND IN LINE WITH THE GUIDELINES ARTICULATED IN THE SALK INSTIUTUTE EXECUTIVE COMPENSATION POLICY. A COMPENSATION COMMITTEE WAS FORMED IN 2014 TO EVALUATE EXECUTIVE COMPENSATION. THE COMMITTEES PURPOSE IS TO ACT ON BEHALF OF THE BOARD OF TRUSTEES TO EVALUATE THE PERFORMANCE OF THE PRESIDENT/CEO; TO DETERMINE ON AN ANNUAL BASIS, APPROPRIATE COMPENSATION FOR THE PRESIDENT/CEO, VICE PRESIDENTS AND/OR EQUIVALENT PERSONS; AND TO RECOMMEND TO THE BOARD PLANS AND POLICIES PERTINENT TO THE COMPENSATION FOR THESE EXECUTIVES. THE OPINIONS FROM THE INDEPENDENT CONSULTANT AND HUMAN RESOURCES WERE REVIEWED BY THE COMPENSATION COMMITTEE, THE EXECUTIVE COMMITTEE OF THE BOARD OF TRUSTEES, AND THE FULL BOARD OF TRUSTEES EXCLUDING THE PRESIDENT DUE TO A CONFLICT OF INTEREST WITH RESPECT TO THE COMPENSATION ARRANGEMENTS. THE DELIBERATIONS AND DECISIONS REGARDING THE COMPENSATION ACTIONS WERE INCLUDED IN THE MINUTES OF THE COMPENSATON COMMITTEE MEETING, THE EXECUTIVE COMMITTEE MEETING AND THE FULL BOARD OF TRUSTEES MEETING. COPIES OF BOTH REPORTS WERE ATTACHED TO THE MINUTES OF THE MEETINGS. DISCLOSURE FORM 990, PART VI, SECTION C, LINE 19 UPON REQUEST, THE OFFICE OF THE CHIEF FINANCIAL OFFICER MAKES AVAILABLE TO THE PUBLIC THE INSTITUTE'S GOVERNING DOCUMENTS AND CONFLICT OF INTEREST POLICY. FINANCIAL STATEMENTS ARE AVAILABLE ON THE SALK WEB SITE. OTHER CHANGES IN NET ASSETS FORM 990, PART XI, LINE 9 POSTRETIREMENT BENEFIT CHANGES OTHER THAN NET PERIODIC BENEFIT COST - $556,360; UNRELATED BUSINESS INCOME $(36,544); ROUNDING - $4. COMPENSATION OF DIRECTORS FORM 990, PART VII, DIRECTORS COMPENSATION THE FOLLOWING INDIVIDUALS WERE COMPENSATED FOR THE FOLLOWING SERVICES AND NOT PAID AS TRUSTEES: EDWARD M. CALLAWAY, PH.D. - PROFESSOR; MARTIN HETZER, PH.D. - PROFESSOR, ALAN SAGHATELIAN, PH.D. - PROFESSOR. LA JOLLA BIOLOGICAL LABORATORIES 10010 N TORREY PINES ROAD LA JOLLA CA 92037 953655649 Research CA 501(C)(3) 11-I NA true SALK INSTITUTE COMMERCIAL SERVICES CORP 10010 N TORREY PINES ROAD LA JOLLA CA 920371002 232159172 MGMT SERVICES PA SALK INSTITUTE C 13 39662 1.00000 true CHARITABLE REMAINDER TRUSTS (7) SUPPORT CA NA TRUST false false false false false false false false false false false false false true true false true false false NONE